The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Market Value Of The Systemic Amyloidosis Therapeutic Market Projected To Expand During 2026–2030?

The systemic amyloidosis therapeutic market size has experienced robust expansion in recent times. This market is projected to expand from $5.67 billion in 2025 to $6.2 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. Factors contributing to its historical growth include the past underdiagnosis of amyloidosis, the prevailing use of chemotherapy regimens, an increase in hematology treatment centers, a rise in awareness regarding rare diseases, and the initial adoption of proteasome inhibitors.

The systemic amyloidosis therapeutic market size is poised for significant expansion in the upcoming years. It is forecast to achieve a valuation of $8.88 billion by 2030, advancing at a compound annual growth rate (CAGR) of 9.4%. This projected increase during the forecast period stems from factors such as increasing rates of rare disease diagnosis, the broader availability of targeted biologic drugs, a rise in approvals for gene silencing therapies, the growth of specialized clinic networks, and more robust incentives for orphan drugs. Noteworthy trends anticipated in this period encompass targeted amyloid protein stabilizer medications, gene silencing treatments for amyloidosis, therapies utilizing monoclonal antibodies, combined treatment protocols, and supportive drug approaches specific to various organs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33337&type=smp

Which Major Factors Are Contributing To The Development Of The Systemic Amyloidosis Therapeutic Market?

The increasing use of personalized medicine methods is set to boost the systemic amyloidosis therapeutic market in the coming years. Personalized medicine is a healthcare strategy that tailors treatment and prevention plans based on an individual’s genetic makeup, biological markers, and specific disease traits. The demand for personalized medicine is on the rise due to advancements in genomic and biomarker technologies, which empower clinicians to accurately pinpoint disease drivers and customize therapies, thereby improving effectiveness and reducing negative side effects for patients. The integration of personalized medicine elevates the need for systemic amyloidosis therapeutics because patients with systemic amyloidosis display distinct amyloid subtypes (e.g., AL, ATTR) and genetic variations, meaning successful treatment requires therapies specifically designed to target each patient’s unique disease profile to ensure optimal effectiveness and minimal adverse reactions. For instance, in April 2025, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit advocacy and educational organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, a substantial increase from six in 2022. Consequently, the expanding adoption of personalized medicine approaches is stimulating the growth of the systemic amyloidosis therapeutic market.

How Is Segment Classification Applied In The Systemic Amyloidosis Therapeutic Market?

The systemic amyloidosis therapeutic market covered in this report is segmented –

1) By Product Type: Small Molecule Drugs; Biologic Therapies; Monoclonal Antibodies; Chemotherapy Based Regimens; Targeted Therapies; Supportive Treatments

2) By Formulation: Tablets; Capsules; Injection

3) By Route of Administration: Oral; Intravenous; Subcutaneous

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

5) By End User: Hospitals; Specialty Clinics; Specialty Pharmacies; Research and Academic Institutes; Other End Users

Subsegments:

1) By Small Molecule Drugs: Proteasome Inhibitors; Stabilizers of Transthyretin Protein; Amyloid Fibril Disruptors; Immunomodulatory Small Molecules

2) By Biologic Therapies: Recombinant Protein Therapies; Gene Silencing Biologic Agents; Plasma Derived Biologic Products

3) By Monoclonal Antibodies: Anti Amyloid Fibril Antibodies; Anti Light Chain Antibodies; Targeted Clearance Antibodies

4) By Chemotherapy Based Regimens: Alkylating Agent Based Regimens; Proteasome Inhibitor Based Chemotherapy; Combination Chemotherapy Protocols

5) By Targeted Therapies: Targeted Light Chain Suppression Therapies; Targeted Transthyretin Reduction Therapies; Organ Specific Targeted Treatments

6) By Supportive Treatments: Cardiac Supportive Therapies; Renal Supportive Therapies; Neurological Symptom Management Therapies; Nutritional and Palliative Care Therapies

Which Trends Are Supporting The Evolution Of The Systemic Amyloidosis Therapeutic Market?

Leading companies operating in the systemic amyloidosis therapeutic market are prioritizing the development of advanced targeted treatment approaches, such as RNA interference-based therapies. These aim to address the fundamental genetic causes of protein misfolding disorders, thereby reducing disease progression and improving long-term patient outcomes. RNA interference-based therapies function by selectively silencing disease-causing genes, which in turn diminishes the production of harmful proteins responsible for systemic organ damage. For instance, in March 2025, Alnylam Pharmaceuticals, a US-based biotechnology company, launched AMVUTTRA. AMVUTTRA provides a targeted, disease-modifying treatment for adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Developed by Alnylam Pharmaceuticals, it stands as the first RNAI therapeutic proven to reduce cardiovascular death, hospitalizations, and urgent heart failure visits within this specific patient population. AMVUTTRA works by promptly suppressing transthyretin production at its source, directly addressing the underlying cause of amyloid deposition. It consistently demonstrates benefits across cardiovascular outcomes, functional capacity, and quality of life.

Who Are The Major Companies Operating In The Systemic Amyloidosis Therapeutic Market?

Major companies operating in the systemic amyloidosis therapeutic market are Johnson & Johnson Services Inc., Sanofi SA, Novartis Plc, AstraZeneca Plc, GSK Plc, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals, Arcturus Therapeutics Inc, Prothena Biosciences, Fortress Biotech Inc., Intellia Therapeutics Inc., Zentalis Pharmaceuticals Inc., BridgeBio Pharma Inc., Neurimmune AG, HaemaLogix Pty Ltd., Attralus Inc., and Oncopeptides AB.

Access The Complete Systemic Amyloidosis Therapeutic Market Report:

https://www.thebusinessresearchcompany.com/report/systemic-amyloidosis-therapeutic-market-report

Which Region Holds The Largest Share In The Systemic Amyloidosis Therapeutic Market?

North America was the largest region in the systemic amyloidosis therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic amyloidosis therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Systemic Amyloidosis Therapeutic Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model